Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.

Orphan Drug Designation to sirolimus in Sickle Cell Disease

RP announcement - read more

The European Commission grants Orphan Drug Designation to Neupharma for the use of Teicoplanin in Cystic Fibrosis, a program developed in collaboration with Rare Partners

RP announcement - read more

Rare Partners supports the IIT for the development of an innovative artificial retina 

RP announcement - read more
Syndicate content